Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma.
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Sorafenib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 26 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Sep 2014 Planned End Date changed from 1 Nov 2013 to 1 Nov 2015 as reported by ClinicalTrials.gov.